drugset / Trial / NCT05477446
Safety and Efficacy of CD207 Targeted CAR-T Cell Therapy in Patients With R/R Langerhans Cell Histiocytosis
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm study to evaluate the efficacy and safety of CD207 targeted CAR-T cell therapy in relapsed and refractory langerhans cell histiocytosis.
Timeline
- Start
- 2022-10-01
- Primary completion
- 2025-06-01
- Completion
- 2025-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD207 CAR-T cells | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | CD207 CAR-T cells | Cell therapy | 3e+06 cells/kg | Intravenous |
| Subject | CD207 CAR-T cells | Cell therapy | 5e+06 cells/kg | Intravenous |
| Subject | CD207 CAR-T cells | Cell therapy | 1e+07 cells/kg | Intravenous |